Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Fruehauf

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|January 14, 2014
Current clinical indications for plerixaforStefan Fruehauf
Future Oncology (London, England)|March 25, 2006
New strategies for mobilization of hematopoietic stem cellsStefan Fruehauf, Timon Seeger
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2010
Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomesStefan Fruehauf, Guido Tricot
Advances in Therapy|October 16, 2016
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal StudyStefan Fruehauf, Burkhard Otremba, Oliver Stötzer, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 3, 2004
[Stem cells in hematology and oncology]Hartmut Goldschmidt, Gerlinde Egerer, Stefan Fruehauf, et al.
Anticancer Research|July 11, 2006
Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitorsAleksandar Radujkovic, Julian Topaly, Stefan Fruehauf, et al.
Leukemia & Lymphoma|March 23, 2002
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemiaJolanta Perz, Julian Topaly, Stefan Fruehauf, et al.
BMC Cancer|November 19, 2013
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropeniaDidier Kamioner, Stefan Fruehauf, Fréderic Maloisel, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2009
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cellsAleksandar Radujkovic, Stefan Fruehauf, W Jens Zeller, et al.
Journal of Virology|July 29, 2006
Viral determinants of integration site preferences of simian immunodeficiency virus-based vectorsHella Monse, Stephanie Laufs, Seraphin Kuate, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|January 14, 2014
Current clinical indications for plerixaforStefan Fruehauf
Future Oncology (London, England)|March 25, 2006
New strategies for mobilization of hematopoietic stem cellsStefan Fruehauf, Timon Seeger
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2010
Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomesStefan Fruehauf, Guido Tricot
Advances in Therapy|October 16, 2016
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal StudyStefan Fruehauf, Burkhard Otremba, Oliver Stötzer, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 3, 2004
[Stem cells in hematology and oncology]Hartmut Goldschmidt, Gerlinde Egerer, Stefan Fruehauf, et al.
Anticancer Research|July 11, 2006
Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitorsAleksandar Radujkovic, Julian Topaly, Stefan Fruehauf, et al.
Leukemia & Lymphoma|March 23, 2002
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemiaJolanta Perz, Julian Topaly, Stefan Fruehauf, et al.
BMC Cancer|November 19, 2013
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropeniaDidier Kamioner, Stefan Fruehauf, Fréderic Maloisel, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2009
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cellsAleksandar Radujkovic, Stefan Fruehauf, W Jens Zeller, et al.
Journal of Virology|July 29, 2006
Viral determinants of integration site preferences of simian immunodeficiency virus-based vectorsHella Monse, Stephanie Laufs, Seraphin Kuate, et al.
Pageof 7